EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudieOpen Access · CC BY 4.0

A comparison of progesterone via vaginal oil capsules versus pessaries for luteal phase support in assisted reproduction treatment: a multicentre cohort study of 42 291 cycles

R K Dhillon-Smith iD, M Khairy, T Bamford iD, V Sephton, A Richardson iD, A H Balen, A Coomarasamy iD

Human Reproduction · 2026

DOI: 10.1093/humrep/deaf219 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Human Reproduction, 2026. Verfasst von R K Dhillon-Smith und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism and Systems Science, School of Medical Sciences, Tommy's National Centre for Miscarriage Research, University of Birmingham,…. Hauptthemen laut MEDLINE: Progesterone, Luteal Phase, Reproductive Techniques, Assisted. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Birmingham Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY QUESTION What is the effect of progesterone administered via vaginal oil capsules versus pessaries, on clinical outcomes, when used for luteal phase support (LPS) in ART? SUMMARY ANSWER Our study findings indicate a higher live birth rate with vaginal oil capsules compared with pessaries, in both fresh and frozen cycles; in the frozen cycles, a lower miscarriage rate was observed with vaginal oil capsules compared with pessaries. WHAT IS KNOWN ALREADY Sufficient LPS, with exogenous progesterone, is essential during ART to improve implantation and pregnancy rates. Micronized vaginal progesterone (MVP) is the most commonly used form of luteal support worldwide. There are no head-to-head comparisons of vaginal oil capsules versus pessaries, with a focus on clinical efficacy, for LPS. STUDY DESIGN, SIZE, DURATION Retrospective cohort study of patients who completed ART cycles with either only vaginal oil capsules 600–800 mg/day or only pessaries 800 mg/day for LPS. Primary outcomes were live birth and miscarriage. Data for fresh IVF/ICSI cycles and frozen embryo transfer cycles with hormone replacement therapy (HRT-FET) were analysed separately. Multivariable regression analyses were performed with adjustment for female age, BMI, ethnicity, ovarian reserve, duration and cause of subfertility, stimulation protocol, number of previous cycles, number of oocytes, number of embryos transferred, previous live births, and previous miscarriages. PARTICIPANTS/MATERIALS, SETTING, METHODS Our study population consisted of women undergoing treatment across 14 Care Fertility clinics in the UK, from January 2017 to December 2022. We included women with stimulated IVF/ICSI cycles with fresh embryo transfer and autologous HRT-FET cycles. A total of 42 291 cycles were analysed; vaginal oil capsules were exclusively used in 25 738 cycles and pessaries exclusively in 16 553 cycles. MAIN RESULTS AND THE ROLE OF CHANCE In the IVF/ICSI group, the live birth rate was higher in those taking vaginal oil capsules compared with pessaries: 34.3% vs 27.8%; adjusted risk ratio (aRR) 1.11 (95% CI 1.04–1.19; P < 0.001). In the HRT-FET group, the live birth rate was also higher in those taking vaginal oil capsules compared to pessaries: 36.7% vs 32.9% (aRR 1.09; 95% CI 1.04–1.14; P < 0.001). The miscarriage rate was lower in those taking vaginal oil capsules compared to pessaries for both IVF/ICSI (13.4% vs 14.5%, P < 0.05) and HRT-FET cycles (17.2% vs 19.7%, P < 0.001) in the crude analysis. The adjusted analysis for miscarriage found a statistically significant difference only for HRT-FET cycles (aRR 0.87; 95% CI 0.82–0.93). LIMITATIONS, REASONS FOR CAUTION This is a retrospective cohort study. Whilst we have extensively adjusted for confounding, there can still be residual confounding. WIDER IMPLICATIONS OF THE FINDINGS An appropriately powered randomized controlled trial directly comparing the two drugs, focusing on clinical efficacy, is required to determine if one is superior to the other. STUDY FUNDING/COMPETING INTEREST(S) This study has been delivered through the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC). R.K.D.S. is in receipt of honoraria for lectures and presentations from Ferring Pharmaceuticals and Besins Healthcare UK. R.K.D.S. has received travel support from IBSA Pharma and Theramex UK and payment for participation on an advisory board for educational meetings for Ferring Pharmaceuticals and IBSA Pharma. A.C. has contributed to the scientific advisory boards of Ferring Pharmaceuticals, Theramax UK, Besins Healthcare UK, and Organon Pharma UK. M.K. has received travel support from Besins Healthcare UK and Merck. A.H.B. is on an advisory board and has received speaker fees from NovoNordisk Pharmaceuticals and is a shareholder at Care Fertility UK and Care Fertility Leeds. T.B. is in receipt of honoraria for lectures and presentations from Merck and Gedeon Richter. T.B. has received travel support from IBSA Pharma, Vitrolife, and Theramex and payment for participation on an advisory basis for IBSA Pharma and Conceivable Life Sciences. A.R. has received honoraria for lectures and presentations from Gedeon Richter. A.R. has received travel support from Gedeon Richter and payment for participation on an advisory board for educational meetings for Ferring Pharmaceuticals. V.S. has received travel support from IBSA Pharma and payment for educational meetings and participation in an advisory role for Theramex. TRIAL REGISTRATION NUMBER n/a

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgesteroneLuteal PhaseReproductive Techniques, AssistedHumansFemalePregnancyAdultRetrospective StudiesAdministration, IntravaginalPregnancy RateLive BirthAbortion, SpontaneousCapsulesBirth RateEmbryo Transfer

Stichwörter der Autor:innen

ARTFETfrozen embryo transferluteal phase supportmiscarriageprogesterone

Substanzen

ProgesteroneCapsules

Autor:innen und Institutionen

  • Department of Metabolism and Systems Science, School of Medical Sciences, Tommy's National Centre for Miscarriage Research, University of Birmingham, Edgbaston, UK.
  • National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK.
  • Care Fertility Birmingham, Birmingham, UK.
  • Care Fertility Manchester, Manchester, UK.
  • Care Fertility Group, Nottingham, UK.
  • Care Fertility Northampton, Northampton, UK.

ORCID-Profile: R K Dhillon-Smith, T Bamford, A Richardson, A Coomarasamy

Förderung

  • National Institute for Health and Care Research
  • Birmingham Biomedical Research Centre

Zitieren

APA

Dhillon-Smith, R. K., Khairy, M., Bamford, T., Sephton, V., Richardson, A., Balen, A. H., & Coomarasamy, A. (2026). A comparison of progesterone via vaginal oil capsules versus pessaries for luteal phase support in assisted reproduction treatment: a multicentre cohort study of 42 291 cycles. Human Reproduction. https://doi.org/10.1093/humrep/deaf219

Vancouver

Dhillon-Smith RK, Khairy M, Bamford T, Sephton V, Richardson A, Balen AH, et al. A comparison of progesterone via vaginal oil capsules versus pessaries for luteal phase support in assisted reproduction treatment: a multicentre cohort study of 42 291 cycles. Human Reproduction. 2026. doi:10.1093/humrep/deaf219

BibTeX
@article{DhillonSmith2026,
  author = {Dhillon-Smith, R K and Khairy, M and Bamford, T and Sephton, V and Richardson, A and Balen, A H and Coomarasamy, A},
  title = {A comparison of progesterone via vaginal oil capsules versus pessaries for luteal phase support in assisted reproduction treatment: a multicentre cohort study of 42 291 cycles},
  journal = {Human Reproduction},
  year = {2026},
  doi = {10.1093/humrep/deaf219}
}
Kostenlos starten →